SOURCE: Paragon Financial Limited

Paragon Financial Limited

June 01, 2012 08:20 ET

Drug Manufacturers Look to Benefit as Senate Approves Plan to Speed Up FDA Reviews

The Paragon Report Provides Stock Research on Johnson & Johnson and Eli Lilly & Co.

NEW YORK, NY--(Marketwire - Jun 1, 2012) - Lost revenues as a result of expiring patents have been a growing problem for the big pharmaceutical companies. New products that are being introduced into the market place are not expected to generate the same levels of revenues of top selling drugs that have lost patent protection. Drug manufacturers and medical device companies will look to get a boost as a $6.4 billion plan to speed up FDA reviews was recently approved by the Senate. The Paragon Report examines investing opportunities in the Drug Manufacturers Industry and provides equity research on Johnson & Johnson (NYSE: JNJ) and Eli Lilly & Co. (NYSE: LLY).

Access to the full company reports can be found at:

www.ParagonReport.com/JNJ
www.ParagonReport.com/LLY

The bill, which the Senate voted 96-1, will raise the user fees the industries pay the FDA for reviews by $2 billion over the next five-year period. The House of Representatives could vote on the bill as early as next week. "This bill's passage is a victory for the millions of Americans who need medicines or medical devices and for the kind of cooperation that we see all too rarely in Washington," said Senators Tom Harkin, and Mike Enzi in a statement. The bill will "improve American families' access to lifesaving drugs and medical devices."

Paragon Report releases regular market updates on the Drug Manufacturers Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Johnson & Johnson recently reported that the Food and Drug Administration (FDA) has declined its application to market its one pill a day version of its HIV pill Prezista. The company has stated that it does not have to conduct further trials of the drug to address the FDA's feedback and will respond to the agency as soon as possible.

Eli Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. The company's Jentadueto tablets have been recently recommended for approval for the treatment of adults with type 2 diabetes by the European Medicines Agency.

Paragon Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Paragon Report has not been compensated by any of the above-mentioned companies. We act as independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: www.ParagonReport.com/disclaimer